Pharmacotherapy for older adults with cancer: an English digest of the Japanese clinical practice guidelines, 2nd edition, for urologic cancers

BACKGROUND: Urological malignancies, including urothelial, prostate, and renal cell carcinomas, are common in older adults and increasingly encountered in aging societies. Older and very old patients remain underrepresented in interventional studies, limiting the direct application of trial evidence to geriatric oncology practice. METHODS: The methodology used to develop these guidelines is described in detail in the overview. Briefly, the guidelines were developed according to the Minds 2020 methodology, incorporating systematic reviews, an evidence-to-decision framework, and multidisciplinary consensus. RESULTS: The English digest summarizes the urological section of the second edition of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer and addresses three clinical questions: immune checkpoint inhibitor-based therapy for metastatic urothelial carcinoma, taxane chemotherapy for metastatic hormone-sensitive prostate cancer, and immune checkpoint inhibitor-containing combination therapy for metastatic renal cell carcinoma. Immune checkpoint inhibitor monotherapy or combination therapy is conditionally recommended for older patients with metastatic urothelial carcinoma. Taxane chemotherapy for metastatic hormone-sensitive prostate cancer may be considered for selected older patients after careful evaluation of comorbidities, functional reserve, values, and living circumstances. For metastatic renal cell carcinoma, immune checkpoint inhibitor-containing combination therapy is conditionally recommended for patients aged ≥ 65 years; however, no recommendation is made for those aged ≥ 75 years because of insufficient evidence. CONCLUSIONS: This guideline digest highlights therapeutic advances in urological cancers and the persistent evidence gap in older populations. The guidelines consistently support individualized treatment decisions based on functional status, comorbidities, treatment burden, and patient preferences rather than chronological age alone.

Authors

Institutions

Publication Details

Journal
International Journal of Clinical Oncology
Published
2026-11-17
DOI
https://doi.org/10.1007/s10147-026-03247-0
Primary Topic
Frailty in Older Adults
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacotherapy for older adults with cancer: an English digest of the Japanese clinical practice guidelines, 2nd edition, for urologic cancers

Yoshiyuki Yamamoto, Fumio Nagashima, Ayumu Matsuoka, Yasutaka Sukawa et al.
1 links
International Journal of Clinical Oncology
Frailty in Older Adults
article

Pharmacotherapy for older adults with cancer: an English digest of the Japanese clinical practice guidelines, 2nd edition, for urologic cancers

Yoshiyuki Yamamoto, Fumio Nagashima, Ayumu Matsuoka, Yasutaka Sukawa, Chihiro Nakayama Kondoh, Shintaro Narita, Satoshi Nitta, Takashi Kawahara, Hiroyuki Nishiyama, Taigo Kato
article en

Abstract

BACKGROUND: Urological malignancies, including urothelial, prostate, and renal cell carcinomas, are common in older adults and increasingly encountered in aging societies. Older and very old patients remain underrepresented in interventional studies, limiting the direct application of trial evidence to geriatric oncology practice. METHODS: The methodology used to develop these guidelines is described in detail in the overview. Briefly, the guidelines were developed according to the Minds 2020 methodology, incorporating systematic reviews, an evidence-to-decision framework, and multidisciplinary consensus. RESULTS: The English digest summarizes the urological section of the second edition of the Japanese Clinical Practice Guidelines for Pharmacotherapy in Older Adults with Cancer and addresses three clinical questions: immune checkpoint inhibitor-based therapy for metastatic urothelial carcinoma, taxane chemotherapy for metastatic hormone-sensitive prostate cancer, and immune checkpoint inhibitor-containing combination therapy for metastatic renal cell carcinoma. Immune checkpoint inhibitor monotherapy or combination therapy is conditionally recommended for older patients with metastatic urothelial carcinoma. Taxane chemotherapy for metastatic hormone-sensitive prostate cancer may be considered for selected older patients after careful evaluation of comorbidities, functional reserve, values, and living circumstances. For metastatic renal cell carcinoma, immune checkpoint inhibitor-containing combination therapy is conditionally recommended for patients aged ≥ 65 years; however, no recommendation is made for those aged ≥ 75 years because of insufficient evidence. CONCLUSIONS: This guideline digest highlights therapeutic advances in urological cancers and the persistent evidence gap in older populations. The guidelines consistently support individualized treatment decisions based on functional status, comorbidities, treatment burden, and patient preferences rather than chronological age alone.

International Journal of Clinical Oncology
University of Tsukuba (JP), Kyorin University (JP), Akita University (JP), Yokohama City University Medical Center (JP), Tokyo Medical Center (JP), Saitama Cancer Center (JP), National Hospital Organization (JP), National Cancer Center Institute for Cancer Control (JP), The University of Osaka (JP)
Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, Jikei University School of Medicine
Good health and well-being
Frailty in Older Adults
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon